The Amyloidosis drugs in development market research report provides comprehensive information on the therapeutics under development for Amyloidosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Amyloidosis. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Amyloidosis and features dormant and discontinued products.

GlobalData tracks 69 drugs in development for Amyloidosis by 54 companies/universities/institutes. The top development phase for Amyloidosis is phase ii with 18 drugs in that stage. The Amyloidosis pipeline has 62 drugs in development by companies and seven by universities/ institutes. Some of the companies in the Amyloidosis pipeline products market are: Alnylam Pharmaceuticals, Attralus and Alexion Pharmaceuticals.

The key targets in the Amyloidosis pipeline products market include Transthyretin (ATTR or Prealbumin or TBPA or TTR), Amyloid Protein And Peptide, and Amyloid Beta A4 Protein (ABPP or APPI or Alzheimer Disease Amyloid Protein or Amyloid Precursor Protein or Amyloid Beta Precursor Protein or Cerebral Vascular Amyloid Peptide or Prea4 or Protease Nexin II or APP).

The key mechanisms of action in the Amyloidosis pipeline product include Transthyretin (ATTR or Prealbumin or TBPA or TTR) Inhibitor with 16 drugs in Pre-Registration. The Amyloidosis pipeline products include seven routes of administration with the top ROA being Intravenous and 13 key molecule types in the Amyloidosis pipeline products market including Small Molecule, and Monoclonal Antibody.

Amyloidosis overview

Abnormal accumulation of amyloid protein in the tissues results in a group of diseases known as amyloidosis. It can affect the shape and functioning of the affected organ, eventually leading to organ failure. Predisposing factors are misfolding of abnormal protein called the light chain and its subsequent deposition in the body. It may also occur as a result of dialysis. Symptoms include fatigue, chest pain, swelling, and breathing problems. Amyloidosis can be managed by transplant and medications such as diuretics and chemotherapy drugs.

For a complete picture of Amyloidosis’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.